

IPW

Date: December 6, 2006

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum  
Name (Print)

Kim Blum  
Signature

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	AKIYAMA et al.	)	Examiner:	Unassigned
		)		
Application No.:	10/594,695	)	Group Art Unit:	Unassigned
		)		
Filed:	September 28, 2006	)	Confirmation No.:	Unassigned
		)		
Docket No.:	3190-101	)	Customer No.:	33432

For: sFRP EXPRESSION ENHANCING AGENT

### **INFORMATION DISCLOSURE STATEMENT** **PURSUANT TO 37 CFR 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

December 6, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO/SB/08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application,

Information Disclosure Statement  
U.S. Patent Application No. 10/594,695


and that the documents cited in the attached Form PTO/SB/08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk  
Reg. No. 33,251

Atty. Docket No.: 3190-101  
KILYK & BOWERSOX, P.L.L.C.  
400 Holiday Court, Suite 102  
Warrenton, VA 20186  
Tel.: (540) 428-1701  
Fax: (540) 428-1720  
Enclosures: PTO/SB/08b w/11 Documents



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Attorney Docket Number

## Complete if Known

Application Number	10/594,695
Filing Date	September 28, 2006
First Named Inventor	AKIYAMA et al.
Art Unit	Unassigned
Examiner Name	Unassigned

3190-101

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HANADA et al., "NE-dlg, A Mammalian Homolog of Drosophila DLG Tumor Suppressor, Induces Growth Suppression and Impairment of Cell Adhesion: Possible Involvement of Down-Regulation of $\beta$ -Catenin by NE-dlg Expression," INT. J. CANCER, No. 86, 2000, pp. 480-488.	
		AKIYAMA, "APC Function and Cancer," JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, Vol. 182, No. 1, 1997, pp. 103-107 (with English translation attached).	
		ELDER et al., "cDNA Sequence and Genomic Structure of the Murine p55 (Mpp1) Gene," GENOMICS, 38, Article No. 0621, 1996, pp. 231-234.	
		MATSUMINE et al., "Binding of APC to the Human Homolog of the Drosophila Discs Large Tumor Suppressor Protein," SCIENCE, Vol. 272, May 17, 1996, pp. 1020-1023.	
		WILLERT et al., "Wnt proteins are lipid-modified and can act as stem cell growth factors," NATURE, Vol. 423, May 22, 2003, pp. 448-452.	
		REYA et al., "A role for Wnt signalling in self-renewal of haematopoietic stem cells," NATURE, Vol. 423, May 22, 2003, pp. 409-414.	
		KAWANO et al., "Secreted antagonists of the Wnt signalling pathway," JOURNAL OF CELL SCIENCE, No. 116, 2003, pp. 2627-2634.	
		JONES et al., "Secreted: Frizzled-related proteins: searching for relationships and patterns," BioESSAYS, No. 24, 2002, pp. 811-820.	
		SUZUKI et al., "Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer," NATURE GENETICS, Vol. 36, No. 4, April 2004, pp. 417-422.	
		XU et al., "Functional and biochemical interactions of Wnts with FrzA, a secreted Wnt antagonist," DEVELOPMENT, No. 125, 1998, pp. 4767-4776.	
		CHANG et al., "Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium," HUMAN MOLECULAR GENETICS, Vol. 8, No. 4, 1999, pp. 575-583.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.